|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Saif MW and CHU E: Biology of colorectal
cancer. Cancer J. 16:196–201. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hühns M, Salem T, Schneider B, Krohn M,
Linnebacher M and Prall F: PTEN mutation, loss of heterozygosity,
promoter methylation and expression in colorectal carcinoma: Two
hits on the gene? Oncol Rep. 31:2236–2244. 2014.PubMed/NCBI
|
|
4
|
Lerman MI and Minna JD: The 630-kb lung
cancer homozygous deletion region on human chromosome 3p21.3:
identification and evaluation of the resident candidate tumor
suppressor genes. The International Lung Cancer Chromosome 3p21.3
Tumor Suppressor Gene Consortium. Cancer Res. 60:6116–6133.
2000.PubMed/NCBI
|
|
5
|
Li J, Wang F, Haraldson K, Protopopov A,
Duh FM, Geil L, Kuzmin I, Minna JD, Stanbridge E, Braga E, Kashuba
VI, et al: Functional characterization of the candidate tumor
suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res.
64:6438–6443. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Senchenko VN, Anedchenko EA, Kondratieva
TT, Krasnov GS, Dmitriev AA, Zabarovska VI, Pavlova TV, Kashuba VI,
Lerman MI and Zabarovsky ER: Simultaneous down-regulation of tumor
suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary
non-small cell lung cancer. BMC Cancer. 10:752010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao Y, Wang J and Fan G: NPRL2 is an
independent prognostic factor of osteosarcoma. Cancer Biomark.
12:31–36. 2012–2013.
|
|
8
|
Otani S, Takeda S, Yamada S, Sakakima Y,
Sugimoto H, Nomoto S, Kasuya H, Kanazumi N, Nagasaka T and Nakao A:
The tumor suppressor NPRL2 in hepatocellular carcinoma plays an
important role in progression and can be served as an independent
prognostic factor. J Surg Oncol. 100:358–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yogurtcu B, Hatemi I, Aydin I and Buyru N:
NPRL2 gene expression in the progression of colon tumors. Genet Mol
Res. 11:4810–4816. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu AY, Liu DG, Du YJ, Pei FH, Yang G, Liu
BR, Zhang HT, Wang XH, Fan YJ, Chen YZ, Jiang Y and Chen J:
Relationship between tumor and peripheral blood NPRL2 mRNA levels
in patients with colorectal adenoma and colorectal cancer. Cancer
Biol Ther. 15:489–495. 2014.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim CH, Kwon S, Bahn JH, Lee K, Jun SI,
Rack PD and Baek SJ: Effects of atmospheric nonthermal plasma on
invasion of colorectal cancer cells. Appl Phys Lett. 96:2437012010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zabarovsky ER, Lerman MI and Minna JD:
Tumor suppressor genes on chromosome 3p involved in the
pathogenesis of lung and other cancers. Oncogene. 21:6915–6935.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wistuba II, Behrens C, Virmani AK, Mele G,
Milchgrub S, Girard L, Fondon JW III, Garner HR, McKay B, Latif F,
Lerman MI, et al: High resolution chromosome 3p allelotyping of
human lung cancer and preneoplastic/preinvasive bronchial
epithelium reveals multiple, discontinuous sites of 3p allele loss
and three regions of frequent breakpoints. Cancer Res.
60:1949–1960. 2000.PubMed/NCBI
|
|
14
|
Wang HL, Liu P, Zhou PY and Zhang Y:
Promoter methylation of the RASSF1A gene may contribute to
colorectal cancer susceptibility: A meta-analysis of cohort
studies. Ann Hum Genet. 78:208–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Li HM, Liu Z, Zhou G, Zhang Q,
Zhang T, Zhang J and Zhang C: Loss of heterozygosity and
methylation of multiple tumor suppressor genes on chromosome 3 in
hepatocellular carcinoma. J Gastroenterol. 48:132–143. 2013.
View Article : Google Scholar
|
|
16
|
Ji L, Nishizaki M, Gao B, Burbee D, Kondo
M, Kamibayashi C, Xu K, Yen N, Atkinson EN, Fang B, Lerman MI, et
al: Expression of several genes in the human chromosome 3p21.3
homozygous deletion region by an adenovirus vector results in tumor
suppressor activities in vitro and in vivo. Cancer Res.
62:2715–2720. 2002.PubMed/NCBI
|
|
17
|
Reed E: Platinum-DNA adduct, nucleotide
excision repair and platinum based anti-cancer chemotherapy. Cancer
Treat Rev. 24:331–344. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ueda K, Kawashima H, Ohtani S, Deng WG,
Ravoori M, Bankson J, Gao B, Girard L, et al: The 3p21.3 tumor
suppressor NPRL2 plays an important role in cisplatin-induced
resistance in human non-small-cell lung cancer cells. Cancer Res.
66:9682–9690. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jayachandran G, Ueda K, Wang B, Roth JA
and Ji L: NPRL2 sensitizes human non-small cell lung cancer (NSCLC)
cells to cisplatin treatment by regulating key components in the
DNA repair pathway. PLoS One. 5:e119942010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kurata A, Katayama R, Watanabe T, Tsuruo T
and Fujita N: TUSC4/NPRL2, a novel PDK1-interacting protein,
inhibits PDK1 tyrosine phosphorylation and its downstream
signaling. Cancer Sci. 99:1827–1834. 2008.PubMed/NCBI
|
|
21
|
Liu X, Wang H, Ma J, Xu J, Sheng C, Yang
S, Sun L and Ni Q: The expression and prognosis of Emi1 and Skp2 in
breast carcinoma: associated with PI3K/Akt pathway and cell
proliferation. Med Oncol. 30:7352013. View Article : Google Scholar : PubMed/NCBI
|
